Study: Most new antibiotics approved by FDA based on non-inferiority trials with surrogate outcomes
Regulatory NewsJeff Craven
Biologics/ biosimilars/ vaccinesClinical TrialsNorth AmericaPharmaceuticalsProduct LifecycleRegulatory NewsJeff CravenBiologics/ biosimilars/ vaccinesClinical TrialsNorth AmericaPharmaceuticalsProduct Lifecycle